European heart health survey 2019

Rising life expectancy in the western population is increasing the prevalence of heart valve diseases (HVD).

[1]  S. Achenbach,et al.  Lower mortality in an all-comers aortic stenosis population treated with TAVI in comparison to SAVR , 2019, Clinical Research in Cardiology.

[2]  M. Toyofuku,et al.  Transcatheter aortic valve implantation versus conservative management for severe aortic stenosis in real clinical practice , 2019, PloS one.

[3]  C. Hamm,et al.  First Experience with the New MitraClip NTR/XTR Device , 2019, Structural Heart.

[4]  J. Leipsic,et al.  Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[5]  F. Musumeci,et al.  Heart Valve Disease Awareness Survey 2017: what did we achieve since 2015? , 2018, Clinical Research in Cardiology.

[6]  A. Cribier,et al.  Assessment of structural valve deterioration of transcatheter aortic bioprosthetic balloon-expandable valves using the new European consensus definition. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[7]  R. Lange,et al.  Beyond the five-year horizon: long-term outcome of high-risk and inoperable patients undergoing TAVR with first-generation devices. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  C. Hamm,et al.  Outcome after transvascular transcatheter aortic valve implantation in 2016 , 2017, European heart journal.

[9]  Jeroen J. Bax,et al.  2017 ESC/EACTS Guidelines for the management of valvular heart disease. , 2017, European heart journal.

[10]  S. Windecker,et al.  Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study , 2017, The Lancet.

[11]  O. Alfieri,et al.  Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique , 2017, Circulation.

[12]  Andrew S. Mugglin,et al.  Surgical or Transcatheter Aortic‐Valve Replacement in Intermediate‐Risk Patients , 2017, The New England journal of medicine.

[13]  M. Pencina,et al.  Comparison of clinical outcomes between bioresorbable vascular stents versus conventional drug-eluting and metallic stents: a systematic review and meta-analysis. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[14]  M. Cilingiroglu,et al.  Predictors of mortality after mitraclip therapy , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[15]  P. Boekstegers,et al.  One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry , 2015, European heart journal.

[16]  R. Swaminathan,et al.  Costs and in-hospital outcomes of transcatheter aortic valve implantation versus surgical aortic valve replacement in commercial cases using a propensity score matched model. , 2015, The American journal of cardiology.

[17]  C. Berry,et al.  The changing course of aortic valve disease in Scotland: temporal trends in hospitalizations and mortality and prognostic importance of aortic stenosis. , 2013, European heart journal.

[18]  B. Carabello.  Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery , 2011, Current cardiology reports.

[19]  B. Carabello.  Aortic stenosis: two steps forward, one step back. , 2007, Circulation.

[20]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.

[21]  Jayant Nath,et al.  Impact of tricuspid regurgitation on long-term survival. , 2004, Journal of the American College of Cardiology.

[22]  Philippe Ravaud,et al.  A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. , 2003, European heart journal.

[23]  J. Chambers,et al.  Predictors of outcome in asymptomatic aortic stenosis. , 2001, The New England journal of medicine.

[24]  Jagmeet P. Singh,et al.  Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) , 1999, The American journal of cardiology.

[25]  C M Otto,et al.  Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. , 1997, Circulation.

[26]  Jeroen J. Bax,et al.  2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. , 2018, Revista espanola de cardiologia.

[27]  R. Saad,et al.  Predictors of outcome in asymptomatic aortic stenosis. , 2001, The New England journal of medicine.

[28]  Keli Glover,et al.  Cohort pro fi le: prevalence of valvular heart disease in community patients with suspected heart failure in UK , 2022 .